{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:34:26Z","timestamp":1772134466837,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110565","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:49:42Z","timestamp":1688140182000},"page":"110565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19"],"prefix":"10.1016","volume":"122","author":[{"given":"Simin","family":"Almasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manizhe Ataee","family":"Kachuee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bentolhoda Mohammad","family":"Shirazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirin","family":"Izadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ghaffarpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Mehdi","family":"Naghizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahin Jamshidi","family":"Makiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitra","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manizheh","family":"Goudarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-5099","authenticated-orcid":false,"given":"Neda","family":"Rahimian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-7095","authenticated-orcid":false,"given":"Tooba","family":"Ghazanfari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2023.110565_b0005","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41385-022-00569-w","article-title":"Role of the humoral immune response during COVID-19: guilty or not guilty?","volume":"15","author":"Yaugel-Novoa","year":"2022","journal-title":"Mucosal. Immunol."},{"key":"10.1016\/j.intimp.2023.110565_b0010","unstructured":"WHO. Therapeutics and COVID-19: living guideline. Accessed August 1, 202. <https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2022.4>."},{"key":"10.1016\/j.intimp.2023.110565_b0015","first-page":"8","article-title":"The efficacy and safety of janus kinase inhibitors for patients With COVID-19: a living systematic review and meta-analysis","author":"Zhang","year":"2021","journal-title":"Front. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110565_b0020","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: current state of the science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2023.110565_b0025","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3389\/fimmu.2020.01844","article-title":"Immunomodulatory drugs in the management of SARS-CoV-2","volume":"11","author":"Burrage","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2023.110565_b0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"JAK-STAT pathway inhibition and their implications in COVID-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad. Med."},{"key":"10.1016\/j.intimp.2023.110565_b0035","article-title":"Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review","volume":"12","author":"Tsai","year":"2020","journal-title":"Therap. Adv. Musculoskel. Disease."},{"key":"10.1016\/j.intimp.2023.110565_b0040","doi-asserted-by":"crossref","first-page":"03","DOI":"10.1590\/1806-9282.2022d681","article-title":"Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib\u2014a biological or synthetic target specific) in patients hospitalized with COVID-19","volume":"68","author":"Barbosa","year":"2022","journal-title":"Rev. Assoc. Med. Bras."},{"issue":"3","key":"10.1016\/j.intimp.2023.110565_b0045","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","article-title":"Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs","volume":"104","author":"Gadina","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2023.110565_b0050","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.trsl.2016.11.006","article-title":"JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa","volume":"188","author":"Boor","year":"2017","journal-title":"Transl. Res."},{"issue":"10229","key":"10.1016\/j.intimp.2023.110565_b0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2023.110565_b0060","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2023.110565_b0065","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1148\/radiol.2020201473","article-title":"CO-RADS: a categorical CT assessment scheme for patients suspected of having COVID-19\u2014definition and evaluation","volume":"296","author":"Prokop","year":"2020","journal-title":"Radiology"},{"issue":"18","key":"10.1016\/j.intimp.2023.110565_b0070","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.intimp.2023.110565_b0075","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","article-title":"COVID-19: a new virus, but a familiar receptor and cytokine release syndrome","volume":"52","author":"Hirano","year":"2020","journal-title":"Immunity"},{"issue":"6490","key":"10.1016\/j.intimp.2023.110565_b0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2023.110565_b0085","article-title":"Interleukin-6 blocking agents for treating COVID-19: a living systematic review","volume":"3","author":"Ghosn","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2023.110565_b0090","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110565_b0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2023.110565_b0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110565_b0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The regulation of JAKs in cytokine signaling and its breakdown in disease","volume":"118","author":"Hammar\u00e9n","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2023.110565_b0110","article-title":"Tofacitinib versus standard of care treatment in patients with COVID-19: a multicenter non-randomized controlled study","author":"Moiseev","year":"2021","journal-title":"Authorea Preprints."},{"issue":"10","key":"10.1016\/j.intimp.2023.110565_b0115","first-page":"1108","article-title":"Tofacitinib associated with reduced intubation rates in the management of severe COVID-19 pneumonia: a preliminary experience","volume":"25","author":"Singh","year":"2021","journal-title":"Ind. J. Crit. Care Med.: Peer-reviewed Off. Publ. Indian Soc. Crit. Care Med."},{"key":"10.1016\/j.intimp.2023.110565_b0120","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397(10285) (2021) 1637\u20131645."},{"key":"10.1016\/j.intimp.2023.110565_b0125","doi-asserted-by":"crossref","first-page":"102039","DOI":"10.1016\/j.pupt.2021.102039","article-title":"Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19","volume":"69","author":"Maslennikov","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2023.110565_b0130","first-page":"605","article-title":"Anti-Inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort","volume":"5","author":"Hayek","year":"2021","journal-title":"Mayo Clinic Proc.: Innov. Qual. Outcomes."},{"issue":"8","key":"10.1016\/j.intimp.2023.110565_b0135","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.jaip.2020.06.015","article-title":"Persistent viral presence determines the clinical course of the disease in COVID-19","volume":"8","author":"Chang","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.intimp.2023.110565_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/JLB.3COVR0520-272R","article-title":"Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts","volume":"108","author":"Wang","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2023.110565_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05730-z","article-title":"JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis","volume":"21","author":"Walz","year":"2021","journal-title":"BMC Infect. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923008883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:20:34Z","timestamp":1736432434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923008883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S1567576923008883"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110565","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of tofacitinib on clinical and laboratory findings in severe and resistant patients with COVID-19","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110565"}}